UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 15, 2004
-------------
ENDOVASC, INC.
(Exact Name of Registrant as Specified in Its Charter)
NEVADA
(State or Other Jurisdiction of Incorporation)
000-28371 76-0512500
(Commission File Number) (IRS Employer Identification No.)
550 CLUB DRIVE, SUITE 440
MONTGOMERY, TEXAS 77316
(Address of Principal Executive Offices) (Zip Code)
(936) 582-5920
(Registrant's Telephone Number, Including Area Code)
ITEM 5. OTHER EVENTS.
Endovasc Incorporated announced that they have entered into a Material Transfer
Agreement (MTA) with a major medical device company for the purpose of
determining whether their prostaglandin E1 (PGE1) technology is suitable for use
on stent coating. This MTA covers the first phase of a project in which a
coating formulation will be developed and evaluated. Endovasc will be
responsible for supplying the drug for testing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
ENDOVASC, INC.
Date: June 15, 2004 By: /s/ Diane Dottavio
------------- -------------------------------
Diane Dottavio,
Chief Executive Officer